OBJECTIVE: Preclinical and clinical studies have shown beneficial effects of infusions of apolipoprotein A-I (ApoA-I) on atherosclerosis. ApoA-I is also a target for myeloperoxidase-mediated oxidation, leading in vitro to a loss of its ability to promote ATP-binding cassette transporter A1-dependent macrophage cholesterol efflux. Therefore, we hypothesized that myeloperoxidase-mediated ApoA-I oxidation would impair its promotion of reverse cholesterol transport in vivo and the beneficial effects on atherosclerotic plaques. APPROACH AND RESULTS: ApoA-I(-/-) or apolipoprotein E-deficient mice were subcutaneously injected with native human ApoA-I, oxidized human ApoA-I (myeloperoxidase/hydrogen peroxide/chloride treated), or carrier. Although early postinjection (8 hours) levels of total ApoA-I in plasma were similar for native versus oxidized human ApoA-I, native ApoA-I primarily resided within the high-density lipoprotein fraction, whereas the majority of oxidized human ApoA-I was highly cross-linked and not high-density lipoprotein particle associated, consistent with impaired ATP-binding cassette transporter A1 interaction. In ApoA-I(-/-) mice, ApoA-I oxidation significantly impaired reverse cholesterol transport in vivo. In advanced aortic root atherosclerotic plaques of apolipoprotein E-deficient mice, native ApoA-I injections led to significant decreases in lipid content, macrophage number, and an increase in collagen content; in contrast, oxidized human ApoA-I failed to mediate these changes. The decrease in plaque macrophages with native ApoA-I was accompanied by significant induction of their chemokine receptor CCR7. Furthermore, only native ApoA-I injections led to a significant reduction of inflammatory M1 and increase in anti-inflammatory M2 macrophage markers in the plaques. CONCLUSIONS: Myeloperoxidase-mediated oxidation renders ApoA-I dysfunctional and unable to (1) promote reverse cholesterol transport, (2) mediate beneficial changes in the composition of atherosclerotic plaques, and (3) pacify the inflammatory status of plaque macrophages.
OBJECTIVE: Preclinical and clinical studies have shown beneficial effects of infusions of apolipoprotein A-I (ApoA-I) on atherosclerosis. ApoA-I is also a target for myeloperoxidase-mediated oxidation, leading in vitro to a loss of its ability to promote ATP-binding cassette transporter A1-dependent macrophage cholesterol efflux. Therefore, we hypothesized that myeloperoxidase-mediated ApoA-I oxidation would impair its promotion of reverse cholesterol transport in vivo and the beneficial effects on atherosclerotic plaques. APPROACH AND RESULTS:ApoA-I(-/-) or apolipoprotein E-deficient mice were subcutaneously injected with native humanApoA-I, oxidized humanApoA-I (myeloperoxidase/hydrogen peroxide/chloride treated), or carrier. Although early postinjection (8 hours) levels of total ApoA-I in plasma were similar for native versus oxidized humanApoA-I, native ApoA-I primarily resided within the high-density lipoprotein fraction, whereas the majority of oxidized humanApoA-I was highly cross-linked and not high-density lipoprotein particle associated, consistent with impaired ATP-binding cassette transporter A1 interaction. In ApoA-I(-/-) mice, ApoA-I oxidation significantly impaired reverse cholesterol transport in vivo. In advanced aortic root atherosclerotic plaques of apolipoprotein E-deficient mice, native ApoA-I injections led to significant decreases in lipid content, macrophage number, and an increase in collagen content; in contrast, oxidized humanApoA-I failed to mediate these changes. The decrease in plaque macrophages with native ApoA-I was accompanied by significant induction of their chemokine receptor CCR7. Furthermore, only native ApoA-I injections led to a significant reduction of inflammatory M1 and increase in anti-inflammatory M2 macrophage markers in the plaques. CONCLUSIONS: Myeloperoxidase-mediated oxidation renders ApoA-Idysfunctional and unable to (1) promote reverse cholesterol transport, (2) mediate beneficial changes in the composition of atherosclerotic plaques, and (3) pacify the inflammatory status of plaque macrophages.
Authors: Jonathan E Feig; Sajesh Parathath; James X Rong; Stephanie L Mick; Yuliya Vengrenyuk; Lisa Grauer; Stephen G Young; Edward A Fisher Journal: Circulation Date: 2011-02-21 Impact factor: 29.690
Authors: Katey J Rayner; Frederick J Sheedy; Christine C Esau; Farah N Hussain; Ryan E Temel; Saj Parathath; Janine M van Gils; Alistair J Rayner; Aaron N Chang; Yajaira Suarez; Carlos Fernandez-Hernando; Edward A Fisher; Kathryn J Moore Journal: J Clin Invest Date: 2011-06-06 Impact factor: 14.808
Authors: Christina A Bursill; Maria L Castro; Douglas T Beattie; Shirley Nakhla; Emiel van der Vorst; Alison K Heather; Philip J Barter; Kerry-Anne Rye Journal: Arterioscler Thromb Vasc Biol Date: 2010-08-11 Impact factor: 8.311
Authors: Lemin Zheng; Megan Settle; Gregory Brubaker; Dave Schmitt; Stanley L Hazen; Jonathan D Smith; Michael Kinter Journal: J Biol Chem Date: 2004-10-21 Impact factor: 5.157
Authors: Cinzia Parolini; Marta Marchesi; Paolo Lorenzon; Mauro Castano; Elena Balconi; Luigi Miragoli; Linda Chaabane; Alberto Morisetti; Vito Lorusso; Bradley J Martin; Charles L Bisgaier; Brian Krause; Roger S Newton; Cesare R Sirtori; Giulia Chiesa Journal: J Am Coll Cardiol Date: 2008-03-18 Impact factor: 24.094
Authors: Eugene Trogan; Jonathan E Feig; Snjezana Dogan; George H Rothblat; Véronique Angeli; Frank Tacke; Gwendalyn J Randolph; Edward A Fisher Journal: Proc Natl Acad Sci U S A Date: 2006-03-01 Impact factor: 11.205
Authors: Bernd Hewing; Saj Parathath; Christina K Mai; M Isabel Fiel; Liang Guo; Edward A Fisher Journal: Atherosclerosis Date: 2013-01-01 Impact factor: 5.162
Authors: Arundhati Undurti; Ying Huang; Joseph A Lupica; Jonathan D Smith; Joseph A DiDonato; Stanley L Hazen Journal: J Biol Chem Date: 2009-09-02 Impact factor: 5.157
Authors: Andrzej Witkowski; Gary K L Chan; Jennifer C Boatz; Nancy J Li; Ayuka P Inoue; Jaclyn C Wong; Patrick C A van der Wel; Giorgio Cavigiolio Journal: FASEB J Date: 2018-01-17 Impact factor: 5.191
Authors: Tessa J Barrett; Emilie Distel; Andrew J Murphy; Jiyuan Hu; Michael S Garshick; Yoscar Ogando; Jianhua Liu; Tomas Vaisar; Jay W Heinecke; Jeffrey S Berger; Ira J Goldberg; Edward A Fisher Journal: Circulation Date: 2019-09-30 Impact factor: 29.690
Authors: Joseph A DiDonato; Kulwant Aulak; Ying Huang; Matthew Wagner; Gary Gerstenecker; Celalettin Topbas; Valentin Gogonea; Anthony J DiDonato; W H Wilson Tang; Ryan A Mehl; Paul L Fox; Edward F Plow; Jonathan D Smith; Edward A Fisher; Stanley L Hazen Journal: J Biol Chem Date: 2014-02-20 Impact factor: 5.157
Authors: Maryam Zamanian-Daryoush; Valentin Gogonea; Anthony J DiDonato; Jennifer A Buffa; Ibrahim Choucair; Bruce S Levison; Randall A Hughes; Andrew D Ellington; Ying Huang; Xinmin S Li; Joseph A DiDonato; Stanley L Hazen Journal: J Biol Chem Date: 2020-02-25 Impact factor: 5.157
Authors: Robert S Rosenson; H Bryan Brewer; Benjamin J Ansell; Philip Barter; M John Chapman; Jay W Heinecke; Anatol Kontush; Alan R Tall; Nancy R Webb Journal: Nat Rev Cardiol Date: 2015-09-01 Impact factor: 32.419